Here are the latest quarterly results of ZYDUS LIFESCIENCES. For more details, see the ZYDUS LIFESCIENCES financial fact sheet and ZYDUS LIFESCIENCES share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
3
Dec-21* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 37,521 | 35,146 | 36,589 | 36,330 | 38,467 | 40,254 | 37,848 | 36,550 | |
Other income | Rs m | 443 | 225 | 275 | 272 | -403 | 316 | 533 | 608 | |
Turnover | Rs m | 37,964 | 35,371 | 36,864 | 36,602 | 38,064 | 40,570 | 38,381 | 37,158 | |
Expenses | Rs m | 29,609 | 27,241 | 28,451 | 28,665 | 29,914 | 30,924 | 29,240 | 29,025 | |
Gross profit | Rs m | 7,387 | 7,905 | 6,818 | 7,665 | 7,822 | 9,330 | 7,651 | 7,525 | |
Depreciation | Rs m | 1,785 | 1,728 | 1,746 | 1,762 | 1,886 | 1,827 | 1,848 | 1,832 | |
Interest | Rs m | 825 | 677 | 452 | 271 | 233 | 273 | 301 | 311 | |
Profit before tax | Rs m | 5,220 | 5,725 | 4,895 | 5,904 | 5,300 | 7,546 | 6,035 | 5,990 | |
Tax | Rs m | 1,085 | 1,182 | 1,000 | 1,045 | -2,016 | 1,415 | 1,000 | 1,107 | |
Profit after tax | Rs m | 4,135 | 4,543 | 3,895 | 4,859 | 7,316 | 6,131 | 5,035 | 4,883 | |
Gross profit margin | % | 19.7 | 22.5 | 18.6 | 21.1 | 20.3 | 23.2 | 20.2 | 20.6 | |
Effective tax rate | % | 20.8 | 20.6 | 20.4 | 17.7 | -38.0 | 18.8 | 16.6 | 18.5 | |
Net profit margin | % | 11.0 | 12.9 | 10.6 | 13.4 | 19.0 | 15.2 | 13.3 | 13.4 | |
Diluted EPS | Rs | 4.0 | 4.4 | 3.8 | 4.7 | 7.1 | 6.0 | 4.9 | 4.8 | |
Diluted EPS (TTM) | Rs | 11.5 | 12.8 | 15.8 | 17.0 | 20.1 | 21.7 | 22.8 | 22.8 | |
![]() |
After opening the day higher, Indian share markets extended gains as the session progressed and ended near the day's high.
A look into the company's quarter four financial performance.
These companies are likely to benefit the most from Covid-19 vaccines.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More